Literature DB >> 18219340

A survey of investigations used for the management of glaucoma in hospital service in the United Kingdom.

P S C Gordon-Bennett1, A S Ioannidis, K Papageorgiou, P S Andreou.   

Abstract

AIMS: This study surveys the current use of investigations for the management of glaucoma in hospital practice by UK ophthalmologists.
METHODS: A total of 1007 questionnaires were posted to all active NHS consultant ophthalmologists. They were asked to indicate the type of hospital (whether university (UTH) or general (DGH) hospital), glaucoma specialist status, and availability and use of automated perimetry, disc photography, HRT, GDx, OCT, and pachymetry.
RESULTS: A total of 493 completed questionnaires were received and 469 were analysed: 284 (60.6%) DGH, 185 (39.4%) UTH, 144 (30.7%) glaucoma specialists. There was good availability of automated perimetry (467, 99.6%), disc photography (420, 89.6%), pachymetry (374, 79.7%), OCT (212, 45.2%), HRT (206, 43.9%), and GDx (59, 12.6%). A total of 308 (65.7%) consultants had at least one digital imaging instrument available. The majority of consultants used SAP (347, 74.0%) and SITA-fast (282, 60.1%) for glaucoma suspects, and for monitoring glaucoma (283, 60.3% and 197, 42.0%, respectively). Some used Esterman (155, 33.0%) and Goldmann fields (90, 19.2%) in addition to SAP and SITA-fast for glaucoma suspects. Few consultants used short-wavelength automated perimetry and frequency-doubled perimetry. Of the three imaging tests, HRT was the most commonly used investigation for disc asymmetry, early glaucoma, glaucomatous progression, ocular hypertension, normal tension glaucoma, and unreliable visual fields (P<0.0001). Where pachymeters were available, 333 (89.0%) consultants and 117 (98.3%) glaucoma specialists used pachymetry in glaucoma management.
CONCLUSIONS: There was some variation in the use of investigations for the diagnosis and management of glaucoma, reflecting the range of techniques available. SAP, SITA-fast, and pachymetry were the most commonly utilised investigations followed by HRT. Glaucoma specialist status, type of hospital, and presence of research influenced the availability and use of all investigations, except visual fields.

Entities:  

Mesh:

Year:  2008        PMID: 18219340     DOI: 10.1038/sj.eye.6703089

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  6 in total

1.  Understanding practice patterns of glaucoma sub-specialists in India.

Authors:  Nikhil S Choudhari; Vanita Pathak-Ray; Sushmita Kaushik; Prateep Vyas; Ronnie George
Journal:  Int J Ophthalmol       Date:  2017-10-18       Impact factor: 1.779

Review 2.  Optic nerve head and fibre layer imaging for diagnosing glaucoma.

Authors:  Manuele Michelessi; Ersilia Lucenteforte; Francesco Oddone; Miriam Brazzelli; Mariacristina Parravano; Sara Franchi; Sueko M Ng; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

3.  Glaucoma management in Sweden -- results from a nationwide survey.

Authors:  Christina Lindén; Boel Bengtsson; Albert Alm; Berit Calissendorff; Ingemar Eckerlund; Anders Heijl
Journal:  Acta Ophthalmol       Date:  2011-10-19       Impact factor: 3.761

4.  Prevalent practice patterns in glaucoma: Poll of Indian ophthalmologists at a national conference.

Authors:  Nikhil Shreeram Choudhari; Vanita Pathak-Ray; Sushmita Kaushik; Prateep Vyas; Ronnie George
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

5.  A Comparative Study between Swedish Interactive Thresholding Algorithm Faster and Swedish Interactive Thresholding Algorithm Standard in Glaucoma Patients.

Authors:  Núria Mendieta; Joel Suárez; Cristina Blasco; Romina Muñiz; Carmen Pueyo
Journal:  J Curr Ophthalmol       Date:  2021-10-22

6.  A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines.

Authors:  Rizwan Malik; Helen Baker; Richard A Russell; David P Crabb
Journal:  BMJ Open       Date:  2013-05-03       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.